Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Tata Capital Growth Fund to Invest Rs 225 Crore in Biocon Biologics for an Equity Stake of 0.85%

Posted On: 2020-07-30 22:37:39


Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced that the Board of its subsidiary Biocon Biologics India Limited (Biocon Biologics) has approved a primary equity investment by Tata Capital Growth Fund. As per the terms of the proposed agreement, Tata Capital will invest Rs 225 Crore for a 0.85% minority stake in the biosimilar business, valuing Biocon Biologics at an equity valuation of Rs 26,250 Crore, or ~USD 3.5 billion, and an enterprise valuation of Rs 30,400 Crore, or ~USD 4.0 billion.

The transaction is subject to standard condition precedents and approvals. Post the completion of this transaction, Biocon will hold 95.25% stake in Biocon Biologics. Dr. Christiane Hamacher, CEO, Biocon Biologics, said: "We are pleased with Tata Capital's investment in Biocon Biologics, which is an endorsement of the value we have created through our demonstrated success and credibility as a global biosimilars player, with two products commercialized in the U.S. and the launch of the third biosimilar on the anvil. We appreciate the conviction of our institutional investors in the 'value creation' story of Biocon Biologics as a fully integrated 'pure-play' global biosimilars company. This equity infusion is the next step in our journey of unlocking value. Through prudent investments in R&D and high-quality manufacturing infrastructure we are confident of achieving our aspiration of serving 5 million patients through our biosimilars portfolio and achieving a target revenue of USD 1 billion in FY22."

Akhil Awasthi, Managing Partner, Tata Growth PE, said: "The fund is delighted to partner with Biocon Biologics, a pre-eminent player in Biopharmaceuticals on a global scale, as part of our focus on export-oriented manufacturing in world beating companies. The investment brings together 150+ years of brand equity of Tata's and a very strong R&D based entrepreneur in Dr Kiran Mazumdar-Shaw with a golden track record of conceptualizing, investing and creating billion-dollar businesses by a meticulous combination of R&D strengths and an exceptional management team".

Sanjay Chaudhary, Partner at Tata Growth PE, added that "this transaction was closed with remarkable efficiency in these challenging times of Covid-19 and demonstrates the strength of the Management team, Advisors and Lawyers advising on this transaction".

The equity infusion by Tata Capital will enable Biocon Biologics' future growth through prudent capital allocation, while we continue our investments in R&D and manufacturing to meet the growing demands of patients worldwide. Having reputed investors as our partners, in the journey of establishing Biocon Biologics, as a leading global player in biosimilars, is reflective of the confidence they have in the company's current and future prospects, aimed at benefiting patients, partners and healthcare systems across the world.

Biocon Biologics is engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to a cutting-edge class of therapies across the world. The company has one of the largest biosimilars portfolios, a wide global footprint, state-of-the-art manufacturing facilities, world-class R&D ecosystem and high quality & compliance standards, enabling it to fulfil unmet needs of patients across the globe. As a company led by innovation and with global scale manufacturing capability to take complex biosimilars to the maximum number of people, Biocon Biologics is well-positioned for the future.

Earlier this month, the Company announced a global collaboration with Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. This makes Biocon Biologics one of the first insulins companies to offer a U.S. Food and Drug Administration-cleared and CE-marked, highly validated digital therapeutic product, Insulia®, to Type 2 diabetes patients, across several markets in the world.

Shares of BIOCON LTD. was last trading in BSE at Rs.403.4 as compared to the previous close of Rs. 395.8. The total number of shares traded during the day was 193713 in over 3470 trades.

The stock hit an intraday high of Rs. 404.75 and intraday low of 395.8. The net turnover during the day was Rs. 77688511.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Wonderla Holidays Ltd announces financial results for Q1FY21

Affle reports strong performance for Q1 FY2021

Magma Fincorp Q1FY21 AUM at Rs 15,922 Cr, PAT at Rs 38 Cr vs Rs 11 Cr YoY

Amber Enterprises India Ltd Q1FY21 loss at Rs. 22.44 crore

Neogen Chemicals Ltd Q1 net profit at Rs. 6.11 crore

Majesco shareholders to receive $16.00 in cash per share, agreement with Thoma Bravo amended

Shilpa Medicare Ltd Q1FY21 consolidated PAT zooms to Rs. 86.31 crore

Magma Fincorp Ltd reports Rs. 37.71 crore consolidated PAT in Q1

VBC Ferro Alloys Ltd posts Q1 loss of Rs. 0.78 crore

Wonderla Holidays Ltd Q1 loss at Rs. 14.51 crore

Rama Phosphates Ltd Q1 PAT up at Rs. 6.56 crore

Shaily Engineering Plastics Ltd posts Rs. 3.02 crore loss in Q1

Shilp Gravures Ltd Q1 net profit at Rs. 0.73 crore

Affle India Ltd posts consolidated net profit of Rs. 18.77 crore in Q1

SPL Industries Ltd Q1 net profit at Rs. 2.64 crore

Fire at Nandan Denim's factory

Avanti Feeds Ltd board to consider Q1 results on Aug 27, 2020

Minda Industries Ltd issues commercial paper of Rs. 25 crore

Info Edge India Ltd closes QIP, fixes issue price as Rs. 3090

Kriti Nutrients Ltd Q1FY21 net profit rises to Rs. 8.16 crore

TVS Electronics Ltd Q1 loss at Rs. 9.75 crore

ZEN Technologies Ltd Q1 loss at Rs. 1.33 crore

DCB Bank Ltd reports Rs. 79.38 crore PAT in Q1FY21

Arihant Capital Markets Ltd Q1FY21 consolidated PAT at Rs. 4.88 crore

RAMCO Systems Ltd posts consolidated PAT of Rs. 13.81 crore in Q1FY21

Bajaj Hindusthan Sugar Ltd Q1 consolidated loss at Rs. 52.89 crore

ARO Granite Industries Ltd Q1 net profit at Rs. 0.34 crore

Nitin Spinners Ltd Q1 loss at Rs. 9.15 crore

Sarda Energy & Minerals Ltd Q1 FY21 consolidated PAT jumps QoQ to Rs. 35.47 crore

Kriti Industries India Ltd Q1 consolidated net profit at Rs. 6.84 crore

Ambika Cotton Mills Ltd posts drop in Q1 PAT to Rs. 5.01 crore

Divi's Laboratories Ltd Q1FY21 consolidated net profit climbs to Rs. 492.06 crore

Geojit Financial Services - Company Update - August 2020 - ICICI Securities

ELGi's AB 'Always Better' Series powers the Indian pharmaceutical industry

Dish TV India to telecast live 'With Sadhguru in Challenging Times' on DishTV and D2H platforms

Newgen's Virtual Meet on Preparing for a Digital-Only World Receives Overwhelming Response

PNB Housing Finance Limited Announces MD & CEO Transition

Canara Bank slashes Interest rates on loans/advances with effect from 07.08.2020

Abbott India Ltd posts Rs. 180.35 crore PAT in Q1FY21

FDC Limited to acquire further stake in South Africa firm

Energy Development Company Ltd board recommends dividend of Rs. 0.50

Hero MotoCorp donates unique first responder vehicles to Civil Hospital, Gurugram

Mirchi revenues fall 72%, but market share rises to 33%

FDC Ltd board approves buy-back at Rs. 450

Gujarat Themis Biosyn Ltd board to approve quarterly results on Aug 13, 2020

Ravileela Granites Ltd Q1 consolidated net profit up at Rs. 0.74 crore

Indowind Energy Ltd posts consolidated PAT of Rs. 3.40 crore in Q1

FDC Ltd reports consolidated PAT of Rs. 91.72 crore in Q1FY21

Mercury Laboratories Ltd Q1 PAT at Rs. 0.96 crore

BATA India Ltd reports loss of Rs. 100.88 crore in Q1FY21







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019